ATC CODE J01DD15

CEFDINIR

Φαρμακολογικό Προφίλ

Πηγή: DrugBank

Περιγραφή & Ένδειξη

Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.

Κύρια Ένδειξη

For the treatment of the respiratory, skin, soft tissue, and ENT infections caused by H. influenzae (including b-lactamase producing strains), H. parainfluenzae (including b-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains), S. pyogenes, S. aureus (including b-lactamase producing strains), and M. catarrhalis.

Χρόνος Ημιζωής

1.7±0.6h

1.7 ± 0.6 hours

Σύνδεση Πρωτεϊνών

60%-70%, binding is independent of concentration.

Δείτε αναλυτικό φαρμακολογικό προφίλ.

+ Περισσότερες Φαρμακολογικές Πληροφορίες

Μηχανισμός Δράσης

As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis by acting on penicillin binding …

Οδός Αποβολής

Cefdinir is not appreciably metabolized. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t½) of 1.7 …